BA Neuschwander-Tetri, SH Caldwell - Hepatology, 2003 - ualberta.ca Fatty liver disease that develops in the absence of alcohol abuse is recognized
increasingly as a major health burden. This report summarizes the presentations
and discussions at a Single Topic Conference held September 20-22, 2002, ... Cited by 828 - Related articles - View as HTML - BL Direct - All 9 versions
- ►stanford.edu [PDF] PD Thompson, P Clarkson, RH Karas - Jama, 2003 - Am Med Assoc Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are
associated with skeletal muscle complaints, including clinically important
myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevations, ... Cited by 585 - Related articles - BL Direct - All 11 versions
- ►zhaoys.com [PDF] DJ Graham, JA Staffa, D Shatin, SE Andrade, … - Jama, 2004 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 341 - Related articles - BL Direct - All 10 versions
- ►ahajournals.org S Bellosta, R Paoletti, A Corsini - Circulation, 2004 - Am Heart Assoc The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) are a well-established class of drugs in the treatment of
hypercholesterolemia, and members of this class have been shown to reduce ... Cited by 240 - Related articles - BL Direct - All 7 versions
RS Rosenson - The American journal of medicine, 2004 - Elsevier Statins are an efficacious and well-tolerated class of lipid-altering agents
that have been shown to reduce the risk of initial and recurrent cardiovascular
events. However, cerivastatin was withdrawn from the world market because ... Cited by 154 - Related articles - All 12 versions
- ►ahajournals.org CJ Vaughan, AM Gotto Jr - Circulation, 2004 - Am Heart Assoc The number of significant developments in the years since the first version of
this review has made necessary an update about the evolving role of
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or ... Cited by 120 - Related articles - BL Direct - All 6 versions
- ►psu.edu [PDF] BM Psaty, CD Furberg, WA Ray, NS Weiss - Jama, 2004 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context In recent years, ... Cited by 115 - Related articles - BL Direct - All 11 versions
V Snow, MD Aronson, ER Hornbake, C Mottur- … - Annals of internal medicine, 2004 - Am Coll Physicians In an effort to provide internists and other primary care physicians with
effective management strategies for diabetes care, the Clinical Efficacy
Assessment Subcommittee (CEAS) of the American College of Physicians (ACP) ... Cited by 96 - Related articles - All 7 versions
AL Huerta-Alardín, J Varon, PE Marik - Crit Care, 2005 - biomedcentral.com Rhabdomyolysis ranges from an asymptomatic illness with elevation in the
creatine kinase level to a life-threatening condition associated with extreme
elevations in creatine kinase, electrolyte imbalances, acute renal failure ... Cited by 91 - Related articles - View as HTML - All 8 versions
H Päivä, KM Thelen, R Van Coster, J Smet, B … - Clinical Pharmacology & Therapeutics, 2005 - nature.com Background: Myopathy, probably caused by 3-hydroxy-3-methylglutaryl-coenzyme A
reductase inhibition in skeletal muscle, rarely occurs in patients taking
statins. This study was designed to assess the effect of high-dose statin ... Cited by 81 - Related articles - All 5 versions
